Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte cultures...

Related Keywords

United States ,San Diego ,California ,University Of Texas ,Texas ,Houston ,American ,Jenene Thomas ,Walter Klemp ,Preliposomal Annamycin Lyophilizate ,Facebook ,Twitter ,Trademark Office ,Properties Of Annamycin ,Securities Exchange ,American Association For Cancer Research ,Linkedin ,Moleculin Biotech Inc ,Exchange Commission ,Nasdaq ,Moleculin Biotech ,American Association ,Cancer Research ,Annual Meeting ,Non Cardiotoxic Properties ,Clinically Evaluated Anthracycline ,Potent Topoisomerase ,Breaking Research ,Molecular Therapeutics ,Chief Executive Officer ,Data Highlights ,United States Patent ,Preliposomal Annamycin ,System Board ,Transcription Modulator ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,